AI Article Synopsis
- - The study aimed to examine how aspirin affects pregnancy outcomes in women with pre-gestational diabetes mellitus (PGDM).
- - Researchers conducted a retrospective audit of PGDM patients from two medical centers, categorizing them into those who took aspirin before 16 weeks and those who did not.
- - Results showed no significant differences in pre-eclampsia rates, pre-term deliveries, or birthweight percentiles between women who took aspirin and those who didn’t.
Article Abstract
Aim: To investigate the effect of aspirin on obstetric outcomes in women with pre-gestational diabetes mellitus (PGDM).
Method: Retrospective audit of pregnant women with PGDM from two centres in South-Western Sydney was conducted. Women were categorised into the aspirin group (prescribed aspirin before 16 weeks, gestation) and non-aspirin group (not prescribed aspirin or prescribed aspirin at or after 16 weeks, gestation). The outcomes examined were pre-eclampsia, pre-term delivery and birthweight percentile.
Results: Of 494 women, 52 (10.5%) were in the aspirin group. Pre-eclampsia developed in 57 (12.0%) women. There was no association between aspirin use and pre-eclampsia (8 (15.4%) vs 49 (11.1%), = 0.2). Aspirin use was not associated with difference in birthweight percentile and rate of pre-term deliveries when adjusted for maternal age, gravidity and other comorbidities.
Conclusion: There was no difference in the rates of pre-eclampsia, pre-term delivery, or birthweight percentile between women with PGDM in aspirin group compared to women in non-aspirin group.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11563550 | PMC |
| http://dx.doi.org/10.1177/1753495X241230719 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!